triggering

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:54 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

Meta Congress and Metaverse superapp to be formed as the result of Catfiz merging with US Meta Alliance.

Source Node:
Time Stamp: September 26, 2022 4:19 AM - Modified On: September 26, 2022 - Published By:
Source Cluster:
Republished By Plato

September 20, 2022 – To achieve lofty purpose of Meta Congress, Edward Musinski (Meta Alliance Corp) and Dr. Fahed Merhebi (Catfiz) are merging the assets into Metabook Sharing Economy platform. Leveraging more than 10-million combined community of students and creators, teaming up with influencers, new company Metabook plans to grow Catfiz to a 100-million-plus base of skilled profs, and to help thousands of Metaverse firms attract more customers, talent, sales and capital, using DAO mechanism. After its acquisition by Zurich Capital Funds in partnership with ML holding, Catfiz provides users with